Interview with Renier Brentjens of Memorial Sloan-Kettering Cancer Center

Email address:

First name:

Last name:

Job title:

Company name:

Country:

I work for

Please specify your industry *

Mobile number:

What is your role?

Unfortunately the document is not available at this current time, however if you leave your details we'll get it to you as soon as we can.

Please fill in all the information requested. It is very important you enter this information correctly so we can contact you with the document.

Remember my details Information

Remember my details

We place a 'cookie' on your computer so next time you visit us you don't need to fill in all these details

close »

We asked Dr. Brentjens some questions revolving around the role of small studies in advancing the development of cell therapies.

Interview questions include:

In your opinion, what is the role and real value of small studies in advancing cell therapies’ research and development?
Is the FDA too stringent when evaluating these experimental approaches, or is it just a matter of adapting these small studies to comply with the current framework for biologics?
Was this recent study experimental to showcase better and faster results when stakeholders in the cell therapy space collaborate? What is missing?
What are the next steps for this trial/experimental therapy? What challenges do you foresee?
Where will funding to continue the development of the therapy come from?
…and more!

To see the answers, get a copy of the interview here.